Israel’s Cannabis Market: 302,000 Imported Flower Packages in One Month and a Booming Research Ecosystem

How does the country that discovered THC import 302,000 flower packages in a single month — and what does a proposed 165% tariff mean for global trade?

Israel occupies a singular position in the global cannabis industry. The country that gave the world the isolation of THC, the discovery of the endocannabinoid system, and decades of pioneering clinical research is also one of the planet’s most import-dependent medical cannabis markets. In a single month, Israeli pharmacies and dispensaries have processed upwards of 302,000 approved flower packages to serve a patient population that peaked at over 140,000 active licence holders in January 2024.

That paradox — a nation with unrivalled scientific expertise in cannabinoids yet reliant on foreign supply for the majority of its flower inventory — defines the strategic tension running through Israel’s cannabis sector in 2025 and into 2026. With a proposed 165% tariff on Canadian imports threatening to reshape trade flows, a sweeping HMO-led prescription reform expanding patient access, and a research ecosystem anchored by over 300 investigators at the Hebrew University alone, Israel’s medical cannabis landscape is one of the most dynamic and consequential in the world.

This analysis breaks down the numbers, the regulatory shifts, and the competitive forces shaping the Israel cannabis market in 2025, and explores what international operators, investors, and researchers need to understand about where this market is headed.

Israel by the Numbers: Market Snapshot

Before diving into the details, the headline figures paint the picture of a market that has grown dramatically but is now entering a period of regulatory recalibration.

The approved flower package data deserves special attention. Measured in units of 10 grams each, the absolute number of approved flower packages rose from 132,000 in August 2019 to a peak of 501,300 in January 2024 — a 279% increase over fewer than five years. By March 2025, this figure had pulled back to 413,400, reflecting the transition from a licence-based model to the new HMO prescription system. The 302,000 figure represents a typical monthly volume during mid-2024, as the market absorbed the effects of the April 2024 regulatory reform.

The Regulatory Framework: From Licences to HMO Prescriptions

Israel’s medical cannabis programme has been shaped by a series of reforms dating back over a decade. The most significant recent change arrived in April 2024, when the Ministry of Health restructured how patients access cannabis.

The Pre-Reform Model (2011–2024)

Under the original system administered by the Israeli Medical Cannabis Agency (IMCA), patients needed a dedicated licence from the Medical Cannabis Unit (IMCU). Only specialist physicians could recommend cannabis, and the process was cumbersome — often limited to patients who had failed multiple conventional therapies. Cannabis was, by design, a treatment of last resort.

Key regulatory milestones in this era included:

• 2019: Transition to per-product pricing, replacing flat-rate pricing models
• 2020: Decentralization of prescription authority to trained physicians outside the IMCU
• 2022: Israel surpassed 33,000 kg of imports, becoming the world’s largest importer of medical cannabis

The April 2024 HMO Reform

The April 2024 reform represented a fundamental shift. For all medical indications except chronic non-cancer pain (CNCP) and PTSD, prescribing authority was delegated to Health Maintenance Organization (HMO) physicians. This moved cannabis into Israel’s universal public healthcare system for the first time.

Under the new model:

• HMO physicians trained and certified in their field of expertise can prescribe medical cannabis as a first-line treatment, not a last resort
• Eligible conditions now include epilepsy, Crohn’s disease, dementia, autism (without age restriction), oncological diseases, multiple sclerosis, HIV/AIDS, and terminal illness
• Patients receive a standard prescription, similar to any other medication
• Any ministry-certified company can supply cannabis products to pharmacies
• The Ministry of Health imposed cost limitations on prescriptions to improve affordability

Approved Indications and Patient Profile

The most commonly approved indication remains chronic non-cancer pain (CNCP), which grew from 53% to 63% of all approved cases between 2019 and 2025. The second-largest category, post-traumatic stress disorder (PTSD), saw approximately 89% growth during the same period, rising from 9% to 17% of active licences.

Approved monthly dosages have also shifted significantly upward. The share of patients receiving 50 grams per month rose by approximately 108%, and those on 60 grams per month increased by roughly 117%, suggesting patients are consuming more cannabis for longer durations as treatment regimens mature.

Import Dependency: Where Israel Gets Its Cannabis

Israel’s medical cannabis market is defined by its reliance on imports. Approximately one-third of all cannabis products consumed in Israel are imported, with the remainder produced domestically by licensed Israeli cultivators. But that import share is strategically critical — it fills a supply gap that domestic production cannot currently close.

Canada: The Dominant Supplier

Canada supplies approximately 80% of Israel’s cannabis imports, with roughly 20 tonnes shipped in 2024 alone, representing about a quarter of total market volume. Major Canadian exporters to Israel include Tilray Brands, Organigram, Village Farms International, and Decibel Cannabis Co.

This concentration of supply in a single origin country has become a point of tension in Israeli trade policy, as domestic cultivators argue that Canadian imports — often sold at lower prices — undercut their operations.

The Global Supply Chain

Beyond Canada, Israel imports cannabis from a diversified network of GMP and GACP-certified suppliers:

Importers must ensure all products meet Israeli regulatory standards, including GACP for cultivation and GMP for manufacturing. Random site inspections, harsh penalties for non-compliance, and batch recalls for quality failures enforce these requirements.

Portugal, the European Hub, and the Israeli Connection

Portugal’s role in the global cannabis supply chain has expanded dramatically, with exports surging from 709 kg in 2019 to more than 33 tonnes in the first eight months of 2025. Over half of Israel’s cannabis exports in 2024 were destined for Portugal, making the two countries significant bilateral trade partners in the medical cannabis space.

For international operators and investors evaluating European market entry, Portugal’s regulatory environment under INFARMED offers a compelling comparison to Israel’s import-heavy model. While weed in Portugal remains strictly regulated for medical use, Portugal’s cannabis laws have created a structured pathway for licensed cultivation and export that feeds into markets like Israel and Germany. Unlike the informal cannabis cafes Portugal is sometimes associated with in popular imagination, the country’s actual cannabis industry is built on pharmaceutical-grade compliance. There are no Portugal weed shops in the recreational sense — the market is entirely medical and research-oriented.

GrowerIQ’s partnership with LEF Lab/InfoSaude in Portugal reflects this growing connection between Portuguese production infrastructure and international compliance requirements. For cultivators considering weed in Lisbon or elsewhere in Portugal as an export base, understanding the EU-GMP certification pathway is essential.

The 165% Tariff Proposal: A Market in Tension

In April 2025, Israeli Economy and Industry Minister Nir Barkat announced plans to impose a 165% "dumping tax" on cannabis imports — a proposal that sent shockwaves through the international supply chain and exposed a deep fault line within Israel’s domestic industry.

The Rationale

The Ministry of Economy launched an investigation into the domestic cannabis market in early 2024 following complaints from local producers that they were struggling to compete on price with Canadian imports. The proposed tariff was designed to remain in force for four years, giving domestic suppliers time to scale production and reach price competitiveness.

Variable Tariff Rates

The proposal did not apply uniformly. Individual Canadian exporters received differentiated rates based on the Ministry’s anti-dumping investigation:

The Opposition

Israeli Finance Minister Bezalel Smotrich opposed the proposal, citing procedural concerns and the need for further evaluation. Patient advocacy groups warned that tariffs would increase costs for consumers, potentially pricing vulnerable patients out of their treatment regimens. Importers argued that domestic production simply could not replace the volume and variety of products currently sourced from Canada.

As of early 2026, the tariff’s status remains uncertain. Barkat may review and resubmit the proposal, but the political dynamics — balancing domestic agricultural interests against patient access and international trade obligations — make a straightforward resolution unlikely.

Israel’s Cannabis Research Ecosystem: A Global Powerhouse

If Israel’s import dependency defines one side of its cannabis market, its research dominance defines the other. No country has contributed more to the foundational science of cannabinoids, and the ecosystem built over six decades continues to drive global advances in cannabis medicine.

The Legacy of Raphael Mechoulam

The story of Israel’s cannabis research begins with Professor Raphael Mechoulam (1930–2023) at the Hebrew University of Jerusalem. In 1964, Mechoulam and his team became the first scientists to isolate and identify delta-9-tetrahydrocannabinol (THC) — the primary psychoactive compound in cannabis. He had earlier been the first to reveal the structure of cannabidiol (CBD) in the early 1960s.

Perhaps more consequentially, Mechoulam’s group went on to discover the endocannabinoid system itself — the network of endogenous neurotransmitters, receptors, and enzymes that regulates cognitive, physiological, and pathophysiological processes including immune function, memory, mood, pain, and psychosis. In 1992, working with William Devane and Lumir Hanus, Mechoulam identified anandamide, the first endocannabinoid neurotransmitter ever found, named after the Sanskrit word for bliss.

Over the course of his career, Mechoulam published more than 425 scientific articles, was elected to the Israel Academy of Sciences and Humanities, and received the Israel Prize for Chemistry Research in 2000. His work laid the scientific foundation for every medical cannabis product and clinical trial in existence today.

The Multidisciplinary Center for Cannabinoid Research (MCCR)

Founded in 2016 at Hebrew University, the MCCR is the world’s largest cannabis research facility. It brings together over 300 investigators, postdoctoral fellows, and PhD students working across 40 research laboratories. The Center’s work spans five core disciplines:

1. Plant research — genetics, cultivation optimisation, and strain development
2. Chemistry — cannabinoid isolation, synthesis, and molecular characterisation
3. Drug development and discovery — novel therapeutic compounds and delivery mechanisms
4. Pharmacology — mechanism of action studies, dose-response modelling
5. Clinical trials — human efficacy and safety studies

The Technion and Broader Institutional Network

Beyond Hebrew University, Professor David "Dedi" Meiri leads the Laboratory of Cancer Biology and Cannabinoid Research at the Technion — Israel Institute of Technology. Meiri’s work focuses on personalised cannabinoid therapy for cancer patients, mapping specific cannabinoid profiles to individual tumour types.

Clinical trials across Israeli institutions are actively investigating cannabis-based treatments for:

• Epilepsy (building on the CBD research that led to Epidiolex)
• Alzheimer’s disease
• Cancer (anti-tumour and palliative applications)
• Crohn’s disease and ulcerative colitis
• PTSD (particularly relevant given the high prevalence in Israeli patient data)
• Fatty liver disease (a recent discovery by Israeli researchers identifying cannabis compounds as potential first-in-class treatments)

This research infrastructure is supported by government policy that has historically favoured cannabis science — a posture that sets Israel apart from most other nations where regulatory barriers have slowed clinical investigation.

Major Israeli Cannabis Companies

Israel’s domestic cannabis industry includes several companies that have built significant scale, though the market has undergone consolidation and competitive disruption in recent years.

Key Players

Tikun Olam — Once Israel’s dominant cannabis brand, Tikun Olam held as much as 40% of the domestic market at its peak. The company, founded in 2005, was instrumental in shaping Israel’s medical cannabis programme and establishing the legitimacy of cannabis-based treatments. However, its market share has declined sharply — to approximately 6% in recent years — and in 2023 reports indicated the company was exploring the sale of its Israeli assets for approximately US$42 million.

InterCure / Canndoc — InterCure, operating through its Canndoc brand, has emerged as one of Israel’s largest cannabis operators. Canndoc held approximately 8% of the market prior to the 2024 reform and has positioned itself for growth under the new HMO-led system.

BOL Pharma — With roughly 10% pre-reform market share, BOL Pharma operates large-scale cultivation and processing facilities and has been active in both domestic sales and export markets.

IM Cannabis Corp. (IMCC) — A publicly traded company that has actively embraced the April 2024 reform, IM Cannabis publicly applauded the implementation of the new HMO prescription model as a pathway to expanded patient access and market growth.

Competitive Dynamics

The domestic market has historically been fragmented, with most companies holding between 6% and 12% of market share. The April 2024 reform, the proposed tariff on Canadian imports, and the ongoing expansion of the patient base are all forces that could drive further consolidation as smaller operators struggle to compete on compliance infrastructure and product breadth.

Export Growth: Israel as a Two-Way Trade Hub

While Israel is best known as an import market, its export activity has grown substantially. In the first nine months of 2025 (January to September), Israel exported approximately 7.47 tonnes of medical cannabis — already surpassing the entire 2024 annual export record of about 4.8 tonnes.

Over half of Israel’s 2024 exports were destined for Portugal, reflecting the growing bilateral trade relationship between the two countries. Other key export destinations include Germany and additional European markets where EU-GMP certification provides a competitive advantage.

For Israeli companies, the export market represents a critical revenue diversification strategy. Domestic pricing pressure — intensified by the tariff debate and the government’s cost limitations on prescriptions — makes higher-margin European sales attractive. However, the EU-GMP compliance burden is significant, and only companies with the most sophisticated quality management systems can consistently meet the requirements of destination-country regulators.

Looking Ahead: Regulatory Reform and Market Expansion

Several developments will shape Israel’s cannabis market over the next 12 to 24 months.

December 2025 Regulatory Expansion

Major regulatory reforms set to take effect in December 2025 will further expand specialist physician authority, streamline patient access pathways, and refresh compliance obligations across the supply chain. Manufacturers, clinics, pharmacies, and importers will need to map current products to new product categories and compile updated compliance evidence.

Patient Growth Projections

Despite the short-term decline from the January 2024 peak of 140,483 patients to approximately 129,900 in March 2025, long-term projections remain bullish. Industry forecasts suggest the patient base could reach approximately 241,782 patients by 2027 — a 70% increase from the December 2023 level of 137,940.

The Tariff Question

The resolution of the 165% tariff proposal will have outsized effects on the supply chain. If implemented in any form, it would likely:

• Increase consumer prices, potentially reducing patient enrolment growth
• Accelerate domestic cultivation investment
• Redirect Canadian export volumes to European markets
• Strengthen Portugal, Colombia, and other non-Canadian suppliers’ competitive position

Research Commercialisation

The translation of Israeli research into commercial products remains an underexploited opportunity. With the pharmaceutical cannabis market projected to reach US$931.4 million by 2030 (a CAGR of 58.1%), companies that can bridge the gap between laboratory discoveries and GMP-manufactured products stand to capture significant value.

How GrowerIQ Supports Operators in the Israeli Cannabis Market

Israel’s market demands operational excellence at every node of the supply chain — from import documentation and batch tracking to research compliance and pharmacy distribution. GrowerIQ’s seed-to-sale platform is built to address precisely these challenges.

Import Tracking and Compliance

For companies importing into Israel, GrowerIQ provides end-to-end traceability that satisfies IMCA requirements. Every flower package — from the 10-gram unit level through to patient dispensing — is tracked with full chain-of-custody documentation. When random site inspections or batch recalls occur, operators using GrowerIQ can produce audit-ready records in minutes, not days.

Research and Clinical Trial Support

Israel’s research institutions require rigorous documentation of cannabis materials used in clinical trials. GrowerIQ’s quality assurance modules support the tracking of cannabinoid profiles, batch provenance, and stability data required for regulatory submissions to ethics committees and the Ministry of Health.

GMP and GACP Compliance for Exporters

Israeli companies exporting to Europe must demonstrate EU-GMP compliance. GrowerIQ’s integrated quality management system tracks every production variable — from cultivation environmental data through to finished product release — generating the documentation required by destination-country regulators in Germany, Portugal, and beyond.

Pharmacy and HMO Distribution

As Israel’s market shifts to HMO-led prescribing, pharmacy distribution chains need real-time inventory visibility across product categories. GrowerIQ’s inventory management tools ensure that pharmacies can track stock levels, expiry dates, and patient allocation across the full product catalogue.

For operators looking to enter or expand in the Israeli market, GrowerIQ provides the compliance infrastructure that turns regulatory complexity into competitive advantage.

This analysis is current as of April 2026 and draws on data from the Journal of Cannabis Research, the Hebrew University Multidisciplinary Center for Cannabinoid Research, Statista and Grand View Research market forecasts, MJBizDaily, and Prohibition Partners industry reporting. Market figures reflect the best available data as of the publication date.

Sources

• Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011–2025 — Journal of Cannabis Research
• Israel medical cannabis patient count hits record as imports soar — MJBizDaily
• Tariff Crisis: Israel’s Cannabis Industry Torn in Two as 165% Import Tax Hangs in the Balance — Business of Cannabis
• The Israeli Medical Cannabis Market: Navigating Tariffs, Trade Wars, and Market Shifts — Cannamonitor
• Cannabis — Israel: Statista Market Forecast
• Israel Cannabis Cultivation Market Size & Outlook, 2030 — Grand View Research
• From Last Resort to First Line: Israel Announces Major Reforms to Medical Cannabis — Business of Cannabis
• New Reforms Set to Send Israeli Medical Cannabis Patient Numbers Soaring — Prohibition Partners
• Multidisciplinary Center for Cannabinoid Research — Hebrew University
• Portugal’s Cannabis Empire: The Heart of European Medical Trade — Cannamonitor
• Israel 2025: Medical Cannabis Rules Expand Specialist Authority — Cannabis Regulations AI
• Israel’s Cannabis Exports Hit New High — Cannabis Law Report "},"caller":{"type":"direct"}}],"stop_reason":"tool_use